IL-4 Predicts the Efficacy of a Candidate Antioxycodone Vaccine and Alters Vaccine-Specific Antibody-Secreting Cell Proliferation in Mice
The Journal of Immunology · 2023
DOI: 10.4049/jimmunol.2200605 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, 2023. Verfasst von Bethany Crouse und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, University of Minnesota Medical School, Minneapolis, MN. Hauptthemen laut MEDLINE: Interleukin-4, Vaccines. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, HHS | NIH | National Institute on Drug Abuse.
Abstract (Originalsprache)
Opioid use disorders (OUDs) are a public health concern in the United States and worldwide. Current medications for OUDs may trigger side effects and are often heavily regulated. A novel treatment strategy to be used alone or in combination with existing medications is active immunization with antiopioid vaccines, which stimulate production of opioid-specific Abs that bind to the target drug and prevent its distribution to the brain. Although antiopioid vaccines have shown promising preclinical efficacy, prior clinical evaluations of vaccines targeting stimulants indicate that efficacy is limited to a subset of subjects who achieve optimal Ab responses. We have previously reported that depletion of IL-4 with a mAb increased opioid-specific IgG2a and total IgG, and it increased the number of germinal centers and germinal center T follicular helper cells in response to antiopioid vaccines via type I IL-4 signaling. The current study further investigates the mechanisms associated with IL-4–mediated increases in efficacy and whether IL-4 depletion affects specific processes involved in germinal center formation, including affinity maturation, class switching, and plasma cell differentiation in mice. Additionally, results demonstrate that preimmunization production of IL-4 after ex vivo whole blood stimulation predicted in vivo vaccine-induced Ab titers in outbred mice. Such mechanistic studies are critical for rational design of next-generation vaccine formulations, and they support the use of IL-4 as a predictive biomarker in ongoing OUD vaccine clinical studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, University of Minnesota Medical School, Minneapolis, MN.
- School of Veterinary Population Medicine, University of Minnesota, St. Paul, MN.
- Center for Immunology, University of Minnesota, Minneapolis, MN.
- Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA.
- Center for Medication Development for Substance Use Disorders, Seattle, WA.
ORCID-Profile: Bethany Crouse, Carly Baehr, Dustin Hicks, Marco Pravetoni
Förderung
- NIDA NIH HHS
- HHS | NIH | National Institute on Drug Abuse
Zitieren
APA
Crouse, B., Baehr, C., Hicks, D., & Pravetoni, M. (2023). IL-4 Predicts the Efficacy of a Candidate Antioxycodone Vaccine and Alters Vaccine-Specific Antibody-Secreting Cell Proliferation in Mice. The Journal of Immunology. https://doi.org/10.4049/jimmunol.2200605
Vancouver
Crouse B, Baehr C, Hicks D, Pravetoni M. IL-4 Predicts the Efficacy of a Candidate Antioxycodone Vaccine and Alters Vaccine-Specific Antibody-Secreting Cell Proliferation in Mice. The Journal of Immunology. 2023. doi:10.4049/jimmunol.2200605
BibTeX
@article{Crouse2023,
author = {Crouse, Bethany and Baehr, Carly and Hicks, Dustin and Pravetoni, Marco},
title = {IL-4 Predicts the Efficacy of a Candidate Antioxycodone Vaccine and Alters Vaccine-Specific Antibody-Secreting Cell Proliferation in Mice},
journal = {The Journal of Immunology},
year = {2023},
doi = {10.4049/jimmunol.2200605}
}
EUVIMED